Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
SinoMab BioScience (03681.HK) Announces First Patient Dosed in China Phase II Trial of SM17 for Atopic Dermatitis
Recommend 2 Positive 1 Negative 0 |
||||
|
||||
|
SinoMab BioScience (03681.HK) announced that on March 31 (yesterday), the first patient has been dosed in China in the Phase II clinical trial of SM17 for the treatment of atopic dermatitis. The Phase II study is a multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of the subcutaneous formulation of SM17 in approximately 210 patients with moderate-to-severe atopic dermatitis. (ha/u) This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
